<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964535</url>
  </required_header>
  <id_info>
    <org_study_id>3103002</org_study_id>
    <nct_id>NCT00964535</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics</brief_title>
  <acronym>KINECO</acronym>
  <official_title>Bioequivalence Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 200/6 µg/Inhalation and Symbicort Turbohaler 200 µg/6 µg/Inhalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with
      the marketed product Symbicort Turbohaler in terms of the drug absorbed into the bloodstream.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters Cmax and AUCt of plasma budesonide and formoterol concentrations</measure>
    <time_frame>within 24 h</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide/formoterol Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Charcoal and Budesonide/formoterol EH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbohaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Charcoal and Symbicort Turbohaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide and formoterol 200/6 microg</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>Budesonide/formoterol Easyhaler</arm_group_label>
    <other_name>Budesonide/formoterol Easyhaler 200/6 microg/inhalation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide and formoterol 200/6 microg</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>Symbicort Turbohaler</arm_group_label>
    <other_name>Symbicort Turbohaler 200/6 microg/inhalation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide and formoterol 200/6 microg</intervention_name>
    <description>2 inhalations as a single dose with the concurrent charcoal blockage</description>
    <arm_group_label>Charcoal and Budesonide/formoterol EH</arm_group_label>
    <other_name>Budesonide/formoterol Easyhaler 200/6 microg/inhalation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide and formoterol 200/6 microg</intervention_name>
    <description>2 inhalations as a single dose with the concurrent charcoal blockage</description>
    <arm_group_label>Charcoal and Symbicort Turbohaler</arm_group_label>
    <other_name>Symbicort Turbohaler 200/6 microg/inhalation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 18-60 years with documented diagnosis of asthma

          -  Prebronchodilator forced expiratory volume in one second (FEV1) at least 80% of the
             predicted value

          -  The asthma should be stable on the same regular treatment for at least 4 weeks before
             screening.

        Exclusion Criteria:

          -  Use of oral, parenteral or rectal corticosteroids within 4 weeks preceding the
             screening

          -  Respiratory infection within 4 weeks preceding the screening

          -  Any condition requiring regular concomitant treatment or likely to need concomitant
             treatment during the study with medicinal products which have pharmacokinetic
             interactions with budesonide

          -  Any disorder or clinically significant abnormal laboratory value or physical finding
             that may interfere with the interpretation of test results or cause a health risk for
             the subject if he/she participates in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulla Sairanen, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>February 12, 2010</last_update_submitted>
  <last_update_submitted_qc>February 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ulla Sairanen</name_title>
    <organization>Orion Corporation, Orion Pharma</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

